THINK is collaborating with the Desmond Tutu TB Center on a study called ChilPreF ML: Children’s preferences between six novel moxifloxacin and linezolid formulations. Researchers have recently developed six new formulations of Moxifloxacin and Linezolid used for TB treatment in children. This study is designed to test the taste preferences of healthy children (aged 5 – 17) for these new medication formulations. In this study, the formulations are prepared with different flavours, and the researchers want to understand which of the preparations are most preferred. The information gained from this taste test will help make recommendations about which formulation(s) of Moxifloxacin and Linezolid to recommend for manufacturers to make available for children. This study started in Feb 2022 and is expected to be completed in the second half of 2022.